验证数据展示
经过测试的应用
Positive WB detected in | HeLa cells, HepG2 cells, MCF-7 cells |
推荐稀释比
应用 | 推荐稀释比 |
---|---|
Western Blot (WB) | WB : 1:1000-1:8000 |
It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
Sample-dependent, Check data in validation data gallery. |
发表文章中的应用
WB | See 7 publications below |
产品信息
29450-1-AP targets BRCA2 in WB, ELISA applications and shows reactivity with Human samples.
经测试应用 | WB, ELISA Application Description |
文献引用应用 | WB |
经测试反应性 | Human |
文献引用反应性 | human |
免疫原 | BRCA2 fusion protein Ag31064 种属同源性预测 |
宿主/亚型 | Rabbit / IgG |
抗体类别 | Polyclonal |
产品类型 | Antibody |
全称 | breast cancer 2, early onset |
别名 | BRCA2, BRCC2, breast cancer 2, early onset, BROVCA2, FACD, FAD, FAD1, FANCB, FANCD, FANCD1 |
计算分子量 | 384 kDa |
观测分子量 | 384 kDa |
GenBank蛋白编号 | NM_000059 |
基因名称 | BRCA2 |
Gene ID (NCBI) | 675 |
RRID | AB_2918309 |
偶联类型 | Unconjugated |
形式 | Liquid |
纯化方式 | Antigen affinity purification |
UNIPROT ID | P51587 |
储存缓冲液 | PBS with 0.02% sodium azide and 50% glycerol , pH 7.3 |
储存条件 | Store at -20°C. Aliquoting is unnecessary for -20oC storage. |
背景介绍
BRCA2, also named as FACD and FANCD1, is involved in double-strand break repair and/or homologous recombination. BRCA2 may participate in S phase checkpoint activation. Defects in BRCA2 are a cause of genetic susceptibility to breast cancer (BC) which also called susceptibility to familial breast-ovarian cancer type 2 (BROVCA2).
实验方案
Product Specific Protocols | |
---|---|
WB protocol for BRCA2 antibody 29450-1-AP | Download protocol |
Standard Protocols | |
---|---|
Click here to view our Standard Protocols |
发表文章
Species | Application | Title |
---|---|---|
Int J Mol Sci CSB Regulates Pathway Choice in Response to DNA Replication Stress Induced by Camptothecin | ||
Aging (Albany NY) A prognostic risk model for programmed cell death and revealing TRIB3 as a promising apoptosis suppressor in renal cell carcinoma | ||
Nucleic Acids Res CSB and SMARCAL1 compete for RPA32 at stalled forks and differentially control the fate of stalled forks in BRCA2-deficient cells | ||
J Enzyme Inhib Med Chem Design, synthesis, and evaluation of novel stilbene derivatives that degrade acidic nucleoplasmic DNA-binding protein 1 (And1) and synergize with PARP1 inhibitor in NSCLC cells | ||
Oncol Lett Olaparib promotes FABP4 expression and reduces antitumor effect in ovarian cancer cells with a BRCA1 mutation | ||
Prostate Combination with vorinostat enhances the antitumor activity of cisplatin in castration-resistant prostate cancer by inhibiting DNA damage repair pathway and detoxification of GSH |